Joshua Bauml, MD of the University of Pennsylvania discusses immunotherapy in lung cancer and the 15-20 percent response rate of unselected patients. Immunotherapy has completely changed the treatment landscape for non-small-cell lung cancer patients. However, not everyone responds well to this therapy. From the trend of the curve, in five years, there is around 15 or 20% progression free survival, which is very interesting. Unfortunately, for unselected patient population, there is only 15-20% response rate. This means it is important to identify better biomarkers to accurately predict the response to these agents.